Germany’s Fresenius SE revises 2016 profit projections up – Earnings in third quarter EUR 399 million

Lower expenditures, the overhaul and launching generic pharmaceutical drugs to the North American market have enabled the German healthcare company Fresenius SE to revise its 2016 profit projections slightly up, following the report on the third quarter results, Wisebroker reports.

The group now expects the adjusted net profit to grow by 12-14% compared to the previous projections of 11-14%, which confirms the company’s good business strategy.

Fresenius made an adjusted profit of EUR 399 million and EUR 7.3 billion of income in the third quarter, which is in line with the market demands.

The main contributors to the growth of income are the infusion solution and equipment production unit Kabi and Fresenius Medical Care, which provides dialysis treatment.

Kabi now expect the income and operating profit to grow by 4-6%, following the recent launch of a generic drug series in the USA, whose market contributes a third of their income.

FMC, which makes two thirds of its income in the North American market and owns 38% of the dialysis market, has made significant advancements following expenditure cuts and the change of operating policy of Medicare, the US national social insurance program.

The company’s revenues in the American market have increased by 10% to USD 3.3 billion, as a result of higher prices of treatments and increased demand by commercial patients, Wisebroker reports.

The FMC Serbia factory in Vrsac is a member of Fresenius Medical Care.

Fresenius Medical Care Srbija Vršac

Fresenius Medical Care AG & Co Germany

Fresenius SE

Fresenius profit

Fresenius income

Fresenius revenues

Fresenius Medical Care

dialysis

generic pharmaceutical drugs

Medicare